HC Wainwright Forecasts Strong Price Appreciation for ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) had its price target increased by equities research analysts at HC Wainwright from $10.00 to $12.00 in a research report issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock.

PRQR has been the topic of a number of other reports. Oppenheimer began coverage on ProQR Therapeutics in a report on Friday, January 10th. They set an "outperform" rating and a $15.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a report on Monday, March 10th. Chardan Capital reissued a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday. Finally, StockNews.com cut ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, November 28th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

Remove Ads

ProQR Therapeutics Stock Down 3.5 %

PRQR traded down $0.06 during trading on Friday, reaching $1.64. 731,927 shares of the company were exchanged, compared to its average volume of 535,512. The company's 50-day moving average is $2.23 and its two-hundred day moving average is $2.62. The company has a market cap of $133.96 million, a price-to-earnings ratio of -5.13 and a beta of 0.24. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PRQR. M&T Bank Corp bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth $330,000. BNP Paribas Financial Markets grew its holdings in shares of ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 7,300 shares during the period. OneDigital Investment Advisors LLC grew its holdings in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 15,550 shares during the period. Ballentine Partners LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $61,000. Finally, Altium Capital Management LLC bought a new stake in ProQR Therapeutics during the fourth quarter valued at about $1,524,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).